This therapy specifically induced HER2-specific immunity, targeting the cells expressing HER2/neu, broke peripheral tolerance to HER2/neu and mediated cytotoxic T-cell–dependent tumor regression (153). This evidence concerns the gene ERBB2 and neoplasm.